Alzheimer's disease (AD) is a neurodegenerative disorder. The current strategies relieve only the symptoms of AD. It is necessary to find therapeutical targets that have an impact on the development of AD. Potential candidates are the vesicular glutamate transporters (vGlut1-3), the glial high-affinity Na+/K+-dependent glutamate transporters (Glt-1 and Glast) and the cystine/glutamate antiporter (with the specific subunit xCT). They are the major determinants of extracellular glutamate levels.
The possible changes in expression levels of these different glutamate transporters are examined in the APP23 transgenic model. The hippocampus and frontal cortex of 8 month old wild type (WT) and APP23 mice are compared.
Glt-1 and Glast showed a significantly down-regulated hippocampal and cortical expression in the APP23 mice. The cortical expression levels of vGlut1 were significantly increased in these mice whereas those of vGlut2, vGlut3 and xCT unchanged. This was also observed for the hippocampal expression of the vGluts and xCT.
These findings suggest the involvement of Glt-1, Glast and vGlut1 in the neurodegenerative process of the APP23 model. Therefore, these glutamate transporters could be important as potential neurobiological targets. Modulation of these transporters might prevent further excitotoxicity and neuronal loss.
This study is currently ongoing with similar experiments in older mice.
Original languageEnglish
Title of host publicationWierzba VI: The tripartite synapse
Publication statusPublished - Aug 2008
EventFinds and Results from the Swedish Cyprus Expedition: A Gender Perspective at the Medelhavsmuseet - Stockholm, Sweden
Duration: 21 Sep 200925 Sep 2009


ConferenceFinds and Results from the Swedish Cyprus Expedition: A Gender Perspective at the Medelhavsmuseet

    Research areas

  • glutamate transporters, APP23 model

ID: 1751576